Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial.
J Dermatolog TreatJul 15, 2026 (epub)
Jinbo Chen, Feng Hu, Ping Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of a phase III randomized controlled trial evaluated the early response to ivarmacitinib in 225 patients with moderate-to-severe atopic dermatitis. The study found that 36.9% of patients were early responders, achieving an EASI 75 response by week 4, which correlated with significantly higher long-term efficacy at week 16, including EASI 75 rates of 81.9% compared to 47.2% in nonearly responders.
Key findings
- Early responders achieved EASI 75 at week 4, with 81.9% vs. 47.2% in nonearly responders at week 16 (p < 0.001).
- Investigator's Global Assessment response rates were 56.6% in early responders compared to 28.9% in nonearly responders (p < 0.001).
- Early responders showed greater improvements in Dermatology Life Quality Index and Patient-Oriented Eczema Measure scores from week 8 to week 52.
Why it matters
Understanding the relationship between early response to treatment and long-term outcomes can help clinicians identify patients who may benefit most from ivarmacitinib, potentially guiding treatment decisions in moderate-to-severe atopic dermatitis.